Y. Crawley

Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models.

J. Klappenbach, Nancy Kelly, M. Cicmil, 2013, European journal of pharmacology.

Inhibition of experimental acute pulmonary inflammation by pirfenidone.

R. Egan, J. Hey, J. Fine, 2003, Pulmonary pharmacology & therapeutics.

Role of nitric oxide on eosinophilic lung inflammation in allergic mice.

R. Egan, M. Minnicozzi, D. Manfra, 1997, American journal of respiratory cell and molecular biology.

Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation.

M. Billah, R. Egan, S. Umland, 1999, American journal of respiratory cell and molecular biology.

Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice.

R. Egan, C. Garlisi, K. Devito, 2001, American journal of respiratory cell and molecular biology.

SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.

M. Billah, R. Egan, M. Corboz, 2002, European journal of pharmacology.

Tachykinin NK3-receptor deficiency does not inhibit pulmonary eosinophilia in allergic mice.

R. Egan, S. Lira, S. Greenfeder, 2004, Pharmacological research.

Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines

W. Kreutner, R. Chapman, B. Luo, 2000, British journal of pharmacology.

Induction of lysosomal and plasma membrane-bound sialidases in human T-cells via T-cell receptor.

M. Billah, R. Egan, H. Bian, 2004, The Biochemical journal.